Over 1.6 million people in the poorest parts of the world are now on antiretroviral treatment to halt the advance of HIV, but in a rush to improve access, mistakes have been made.

In a new AEI Press book, Anupam B. Jena and Tomas J. Philipson argue that health care cost-effectiveness criteria may constrain future innovation.

The United States has been reluctant to purchase and distribute genericAIDS treatments,and this caution has been vindicated.

Taxes and tariffs on medicines and medical devices need to be eliminated in order to bring down the cots of life-saving medications.

It is time the World Health Organizationlost all its AIDS funding until it demonstrates an ability to deal with the disease and not just play to the activist crowd.

The process of treating HIV patients in Africa has improved markedly due to cooperation between pharmaceutical companies, which has led to increasing access to higher quality medicines.

Gordon Brown says he wants to write off all British debt to Africa. Perhaps, as a quid pro quo, he can get African nations to remove financial barriers that harm their poorest.

Experts assess the program in the global fight against AIDS.